【摘要】 本文通过建立具有亚临床病例特点的实验性甲亢和甲低模型，以及通过参照文献的方法建立应用荧光分光光度计测定血浆中普萘洛尔（ｐｒｏｐｒａｎｏｌｏｌ）的方法，研究了甲状腺功能状态对普萘洛尔药物动力学的影响。结果如下：对照组，甲亢组和甲低组大鼠ｉｐ普萘洛尔４ｍｇ／ｋｇ，求得其主要药物动力学参数：Ｔ１／２β（ｈ）分别为４．５４±０．６５，３．５８±０．３５（Ｐ＜０．０５）和６．４±０．８（Ｐ＜０．０５）；Ｋ１０（ｈ－１）分别为０．９９±０．０２，１．２３±０．０９（Ｐ＜０．０１）和０．６６±０．０８（Ｐ＜０．０１）；ＡＵＣ〔ｎｇ／（ｍｌ·ｈ）〕分别为６５４．２±９０．４，４４８．２±６６．８（Ｐ＜０．０１）和１０３４．６±１３２．３（Ｐ＜０．０１）；ＣＬ〔ｍｇ／（ｋｇ·ｈ）／（ｎｇ·ｍｌ）〕分别为０．００６２２±０．０００９６，０．００９１±０．００１６（Ｐ＜０．０１）和０．００３９２±０．０００５８（Ｐ＜０．０１）；Ｃｍａｘ（ｎｇ／ｍｌ）分别为５０１．４６±４０．１３，４０８．３３±５７．６５（Ｐ＜０．０１）和６０７．８±２７．２（Ｐ＜０．０１）。更多还原

【Abstract】 he experimental hyperthyroid and hypothyroidism model with sub clinical characteristics was used,plasma conantration of propranolol was determined with fluorophotometer to study the effect of thyroid functional state on the pharmacokinetics of propranolol.The results were:pharmacokinetic parameters of propranolol following ip 4mg/kg in control,hyperthyroidism and hypothyroidism group rats: T 1/2 β(h) 4.54 ± 0.65 , 3.58 ± 0.35 ( P < 0.05 ) and 6.41 ± 0.8 ( P < 0.05 ),respectively; K 10 (h -1 ) 0.99 ± 0.02 , 1.23 ± 0.09 ( P < 0.01 ) and 0.66 ± 0.08 ( P < 0.001 ),respectively; AUC ng/(ml·h) 654.15 ± 10.45 , 448.19 ± 66.78 ( P < 0.01 ) and 1034.60 ± 132.29 ( P < 0.01 ),respectively; CL mg/(kg·h)/(ng·ml) : 0.00622 ± 0.00096 , 0.00911 ± 0.00155 ( P < 0.01 ) and 0.00392 ± 0.00058 ( P < 0.01 ),respectively; C max (ng/ml) 501.46 ± 40.13 , 408.33 ± 57.65 ( P < 0.01 ) and 607.81 ± 27.24 ( P < 0.01 ),respectively.更多还原